Managers / Q1 2021 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $553M in U.S.-listed holdings across 17 positions for Q1 2021.
Its largest position, SPRO, represents 10.2% of the portfolio.
Compared with Q4 2020, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 49.6% · $275M
- ETP · 33.7% · $187M
- Other · 13.2% · $73M
- ADR · 3.4% · $19M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF TR | NEW | +300.0K | 300.0K | +$119M | $119M |
| HARPOON THERAPEUTICS INC | NEW | +1.55M | 1.55M | +$33M | $33M |
| FDMT4D MOLECULAR THERAPEUTICS IN | ADDED | +280.9K | 300.9K | +$12M | $13M |
| IBBISHARES TR | SOLD OUT | −500.0K | 0 | −$76M | $0 |
| ANABANAPTYSBIO INC | SOLD OUT | −1.22M | 0 | −$26M | $0 |
| ARGXARGENX SE | ADDED | +8.5K | 21.2K | +$2M | $6M |
| GALAPAGOS NV | ADDED | +46.7K | 116.7K | +$2M | $9M |
| QUREUNIQURE NV | ADDED | +253.4K | 955.4K | +$7M | $32M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SPROSPERO THERAPEUTICS INChistory → | COM | 10.19% | $56M | 3.83M |
| 2 | DICERNA PHARMACEUTICALS INC | COM | 7.88% | $44M | 1.71M |
| 3 | BLUEPRINT MEDICINES CORP | COM | 7.43% | $41M | 423.0K |
| 4 | NGM BIOPHARMACEUTICALS INC | COM | 5.91% | $33M | 1.12M |
| 5 | HARPOON THERAPEUTICS INC | COM | 5.88% | $33M | 1.55M |
| 6 | QUREUNIQURE NVhistory → | SHS | 5.82% | $32M | 955.4K |
| 7 | MAGENTA THERAPEUTICS INC | COM | 5.35% | $30M | 2.50M |
| 8 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 4.89% | $27M | 407.9K |
| 9 | RGNXREGENXBIO INChistory → | COM | 3.45% | $19M | 559.4K |
| 10 | FDMT4D MOLECULAR THERAPEUTICS INhistory → | COM | 2.36% | $13M | 300.9K |
| 11 | AMRYT PHARMA PLC | SPONSORED ADS | 2.01% | $11M | 800.0K |
| 12 | PIERIS PHARMACEUTICALS INC | COM | 1.71% | $9M | 3.68M |
| 13 | GALAPAGOS NV | SPON ADR | 1.63% | $9M | 116.7K |
| 14 | ARGXARGENX SEhistory → | SPONSORED ADR | 1.05% | $6M | 21.2K |
| 15 | GMABGENMAB A/S | SPONSORED ADS | 0.71% | $4M | 120.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.